Workflow
皓元医药: 上海皓元医药股份有限公司关于不调整可转换公司债券“皓元转债”转股价格的公告

Core Viewpoint - The company announced that the conversion price of its convertible bonds, "Haoyuan Convertible Bonds," will remain unchanged at RMB 40.58 per share following the completion of its stock incentive plan [1][4][6] Group 1: Convertible Bond Issuance - The company has received approval from the China Securities Regulatory Commission to issue convertible bonds totaling RMB 822.35 million, with a maturity of 6 years and an initial conversion price set at RMB 40.73 per share [1] - The bonds will be listed on the Shanghai Stock Exchange on December 19, 2024, with a total issuance of 822,350 lots (8,223,500 bonds) [1] Group 2: Stock Incentive Plan and Price Adjustment - The company completed the registration of the third vesting period of its 2022 restricted stock incentive plan on June 30, 2025, increasing its total share capital from 210,961,003 shares to 211,609,573 shares [2] - The adjustment of the conversion price is based on the company's stock incentive plan and follows specific formulas outlined in the bond issuance prospectus [3][5] Group 3: Price Adjustment Calculation - The conversion price remains unchanged at RMB 40.58 per share because the total number of shares from the stock incentive plan is relatively small compared to the total share capital [4][6] - The calculation for the conversion price adjustment was performed using the formula for new share issuance, resulting in no change to the conversion price [5][6]